The U.S. And Europe Pharmaceutical Manufacturing Market size was valued at USD 412.50 billion in 2023 and is projected to reach USD 654.20 billion by 2032, exhibiting a CAGR of 6.81 % during the forecasts period. The scope of the U. S. and Europe pharmaceutical manufacturing market includes the manufacturing and creating of the medications as well as the pharmaceutical products. This market comprises activities such as formulation of drugs, manufacturing of the drug, testing and certification of the quality, and placing the drug in the appropriate packaging. Some of the uses include formulating prescription medicines, over the counter drugs, and biopharmaceuticals. Such impacts include; growing enrolment of patients on new techniques, rising incidences of persistent diseases and development of technologies in the production of the equipment. Trends include the transformation from a disease-centered approach to a patient-centered one, the continued rise in the polygenic biological medicines and biological generics, integration of innovative practices of manufacturing like continuous processing and automation, and the need to observe regulatory requirements to satisfy the strict standards of the two regions.

The United States was the largest national pharmaceutical market in 2023, making up around 44 percent of the total pharmaceutical spending worldwide. China is the second-largest market with a market share of seven percent (although including only the hospital market). International differences in drug prices The worldwide pharmaceutical market was valued at approximately 1.6 trillion U.S. dollars in 2023. Sales of pharmaceuticals in the United States generated around 714 billion U.S. dollars in 2023, over 600 billion U.S. dollars more than the second ranked country. One reason for the disparity between countries is the price of prescription medications: in the United States, the prices of branded drugs increased significantly between 2011 and 2019. Many pharmaceutical manufacturers argue that prices need to be raised to not only recoup research costs but also to maintain profit margins because of the larger rebates negotiated by pharmacy benefits managers. Prescription drug prices are a bitter pill to swallow With an average spend of 1,560 U.S. dollars per person, the United States had the highest pharmaceutical spending per capita worldwide in 2022. Brand name medications are particularly expensive in the country: the average price of Humira in the United States is far higher than in other markets. Branded drugs enjoy the protection of patents, and the lack of competition means both manufacturers and pharmacies can charge what the market will bear.

The Pharmaceutical Manufacturing Market Report is Segmented by Molecule Type (Biologics and Biosimilars (Large Molecules) and Conventional Drugs (Small Molecules)), Drug Development Type (Out-House and In-House), Formulation (Tablets, Capsules, Injectables, Sprays, and Other Formulations), Application (Cancer, Diabetes, Cardiovascular Diseases, Neurological Diseases, Respiratory Diseases, and Other Applications), and Prescription Type (Prescription Medications and Over-The-Counter Medications), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

US And Europe Ethanol And Specialty Chemicals In Pharmaceutical Manufacturing Market size was valued at USD 16,940.49 Million in 2023 and is projected to reach USD 22,181.23 Million by 2031, growing at a CAGR of 3.93% from 2024 to 2031.

US And Europe Ethanol And Specialty Chemicals In Pharmaceutical Manufacturing Market Overview

Significant driver is the rising prevalence of biopharmaceuticals and biologics, which require intricate and sensitive manufacturing processes. Ethanol plays an essential role as a solvent, while various specialty chemicals are critical for purification, extraction, and stabilization processes. With increased investments in biotechnology and bio-based products, particularly within the EU, manufacturers are expanding biopharmaceutical production capabilities. For example, Circular Bio-Based Europe (CBBE) has announced a total funding of €213 million (USD 232.08 million) aimed at fostering competitive, circular bio-based industries across Europe.

This statistic describes the global pharmaceutical sales in from 2020 to 2024, sorted by regional submarkets. For 2024, total pharmaceutical sales in the United States was estimated to reach around 760 billion U.S. dollars. World pharmaceutical sales by regionThe pharmaceutical industry is best known for manufacturing pharmaceutical drugs which aim to diagnose, cure, treat, or prevent diseases. The pharmaceutical sector represents a huge industry, with the global market being worth around 1.6 trillion U.S. dollars. Among the best known top global pharmaceutical companies are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Accordingly, North America and Europe are still among the largest global submarkets for pharmaceuticals. In 2024, the United States was still the largest single pharmaceutical market, generating more than 760 billion U.S. dollars of revenue. Europe was responsible for generating around 280 billion U.S. dollars. These two markets, together with Japan, Canada and Australia, form the so-called established (or developed) markets. The rest of the global pharmaceutical revenue is mainly from emerging markets, which include countries like China, Russia, Brazil and India. In fact, these emerging markets show the fastest increase in pharmaceutical sales. Latin America is the world region with the highest predicted compound annual growth rate until 2028.

Snapshot img

Pharmaceutical Contract Manufacturing Market Size 2024-2028

The pharmaceutical contract manufacturing market size is estimated to increase by USD 64.8 billion and grow at a CAGR of 8.1% between 2023 and 2028. The growth of the pharmaceutical market is driven by several key factors, including patent expiration and rising demand for generic drugs, alongside the increasing emphasis on core competencies and robust research funding. However, the market faces challenges such as capacity utilization constraints, the conventional nature of Contract Manufacturing Organizations (CMOs), and stringent regulatory frameworks governing their operations. These elements collectively shape the trajectory of the market, influencing its growth and presenting obstacles that necessitate strategic navigation to ensure sustained development and innovation in pharmaceutical contract packaging. Addressing capacity limitations, transforming the operational landscape of CMOs, and navigating regulatory complexities are imperative for overcoming hurdles and fostering a conducive environment for the pharmaceutical industry's evolution. By leveraging core competencies and research investments, stakeholders can capitalize on emerging opportunities and drive advancements in drug manufacturing while ensuring compliance with evolving regulatory standards.

What will be the Size of the Pharmaceutical Contract Manufacturing Market During the Forecast Period?

To learn more about this pharmaceutical contract manufacturing market report, View Report Sample

Pharmaceutical Contract Manufacturing Market Segmentation

The pharmaceutical contract manufacturing market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in 'USD Billion' for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

End-User Outlook

  Big pharmaceutical companies
  Small and medium-sized pharmaceutical companies
  Generic pharmaceutical companies





Service Outlook

  API/bulk drug manufacturing
  Final dosage form
  Secondary packaging





Region Outlook

  North America

    The U.S.
    Canada





  Europe

    U.K.
    Germany
    France
    Rest of Europe





  Asia

    China
    India





  ROW

    Australia
    Argentina
    Rest of the world

By End-user

The market share growth by the big pharmaceutical companies segment will be significant during the forecast period. Big pharmaceutical companies is a term for the world's largest publicly traded pharmaceutical companies. The largest pharmaceutical companies may also have divisions that produce medical equipment. These companies are usually larger than companies that focus on medical devices alone.

Get a glance at the market contribution of various segments. View the PDF Sample

The big pharmaceutical companies segment was valued at USD 56.20 billion in 2018. In this segment, pharmaceutical clients can extend their technical resources by outsourcing to a CMO without incurring more overhead. CMOs have become more significant in the pharmaceutical sector during the past 25 years. Moreover, the big pharmaceutical companies have also been prioritizing their efforts in their core competencies. Hence, they prefer not to use the existing tools, knowledge, and technology when creating the final dose of medications. Instead of producing the formulated drug to remain competitive in the market, pharmaceutical companies had to review their production techniques and R&D operations. This was due to growing competition and narrowing profit margins. Thus, such partnerships between big pharmaceutical companies and CMOs is expected to drive the growth of the global pharmaceutical contract manufacturing market through the big pharmaceutical companies segment during the forecast period.

By Region

For more insights on the market share of various regions, Download PDF Sample now!

Asia is estimated to contribute 45% to the growth of the global pharmaceutical contract manufacturing market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Another region offering significant growth opportunities to companies is North America. The pharmaceutical contract manufacturing market in North America is experiencing significant growth, driven by increasing demand for cost-effective and efficient drug manufacturing solutions. In recent years, there has been rapid growth in the number of new and innovative drugs entering the market. These drugs are often highly specialized and require specialized manufacturing processes that are not available in-house for pharmaceutical firms. This has led to an increasing dependence on CMOs that have the required expertise and facilities to manufacture these specialized drugs. These factors will fuel

Germany was the leading pharmaceutical market in Europe with a total revenue of nearly 69 billion euros in 2023. France and Italy followed with revenues of 46.5 billion and 40.7 billion euros respectively. The top five were rounded off by Spain and Poland. German pharmaceutical marketWhen the revenue of the German pharmacy market is broken down, it is prescription drugs that account for the majority of the revenues. Prescription medication accounted for around 39 billion euros of revenue, followed by pharmacy-only drugs at some 3.5 billion euros. German pharmaceutical exportsOver a 13-year period, the value of pharmaceutical exports from Germany has skyrocketed. Increasing from approximately 18.8 billion euros in 2000 to some 113 billion euros in 2023. The leading destination for these exports is the United States, followed by the Netherlands and Switzerland.

Pharmaceutical Manufacturing Software Market size was valued at USD 2.84 Billion in 2023 and is projected to reach USD 12.13 Billion by 2030, growing at a CAGR of 22.9% during the forecast period 2024-2030.

Global Pharmaceutical Manufacturing Software Market Drivers

The market drivers for the Pharmaceutical Manufacturing Software Market can be influenced by various factors. These may include:

Strict Standards for Regulatory Compliance: The pharmaceutical sector is bound by stringent laws, which encompass Good Manufacturing Practices (GMP), FDA rules in the US, and additional global standards including EU GMP. Software for pharmaceutical production helps businesses comply with these requirements, which increases demand for software solutions that make paperwork and regulatory compliance easier.

Growing Complexity of Manufacturing Processes: The emergence of biologics, customized medicine, and sophisticated drug delivery systems are some of the reasons contributing to the growing complexity of pharmaceutical manufacturing processes. Pharmaceutical producers benefit from software systems that provide capabilities like batch tracking, real-time monitoring, and process automation, which help them manage complexity and increase operational efficiency

Emphasis on Quality and Risk Management: To guarantee the safety and effectiveness of pharmaceutical products, quality management is crucial in the pharmaceutical sector. Software for pharmaceutical production helps businesses maintain high levels of quality throughout the manufacturing process by giving them tools for risk assessment, deviation management, and quality control.

Expanding Adoption of Industry 4.0 Technologies: Automation, the Internet of Things (IoT), artificial intelligence (AI), and data analytics are some of the technologies that are revolutionizing the pharmaceutical industry. The market for advanced manufacturing software is being driven by software solutions that take advantage of these technologies to help businesses optimize production processes, cut waste, and improve decision-making.

Pharmaceutical firms are facing pressure to enhance their operational efficiency and minimize expenses without compromising on product quality and compliance. Manufacturing software solutions save costs and boost productivity by streamlining manufacturing processes, allocating resources optimally, and minimizing downtime.

Growing Contract Manufacturing Organizations (CMOs) and Contract: Development and Manufacturing Organizations (CDMOs) Outsourcing: A large number of pharmaceutical businesses contract manufacture and develop drugs. Software solutions that facilitate communication, data sharing, and process integration between pharmaceutical companies and their outsourcing partners are therefore becoming more and more necessary.

Transition to Personalized Treatment and Smaller Batch Production: Pharmaceutical producers must adapt and become more nimble in their production methods in light of the move to personalized treatment and smaller batch sizes. Manufacturing software solutions that facilitate flexible scheduling, quick changeover, and batch customization enable businesses to adjust to the shifting needs of small-batch production and tailored treatment.

Globalization of Pharmaceutical Supply Chains: With production facilities dispersed over several nations and regions, pharmaceutical supply chains are becoming more and more global. Pharmaceutical organizations benefit from manufacturing software solutions that include multilingual support, multi-site capability, and regulatory compliance features for effective management of global supply chains.

Emphasis on Data Integrity and Security: Given the sensitive nature of data related to pharmaceutical manufacturing, data integrity, and security are major issues in the pharmaceutical sector. Software solutions that guarantee data encryption, access control, and integrity are manufactured to assist businesses in adhering to data privacy laws and safeguarding their intellectual property.

The rise of cloud-based manufacturing software solutions: As opposed to conventional on-premises software systems, cloud-based manufacturing software solutions are more affordable, scalable, and easily accessible. Because of its flexibility, ability to collaborate in real-time, and reduced initial expenses, cloud-based manufacturing software is becoming more and more popular among pharmaceutical organizations.

Snapshot img

Pharmaceutical Equipment Market Size 2025-2029

The pharmaceutical equipment market size is forecast to increase by USD 6.38 billion at a CAGR of 6.9% between 2024 and 2029.

The market is witnessing significant growth due to several key trends. The rising prevalence of diseases and the subsequent increase in demand for pharmaceuticals are major growth factors. Standardization across pharmaceutical equipment is another trend driving market growth. However, the high cost of pharmaceutical equipment remains a challenge for market expansion. Despite this, advancements in technology and automation are expected to provide opportunities for market growth. Automation, robotics, artificial intelligence, and machine learning are becoming increasingly important in the market. Overall, the market is anticipated to experience steady growth in the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The pharmaceutical industry is experiencing significant growth due to the aging population and the rising prevalence of chronic health conditions, including chronic diseases such as cancer, diabetes, and cardiovascular disease. This trend is driving the demand for advanced pharmaceutical equipment to meet the increasing production requirements and ensure the production of personalized medicines based on genetic information. These technologies enable the industry to improve efficiency, reduce costs, and ensure regulatory compliance. The use of automation and robotics in the production process allows for the streamlining of supply chain operations, optimizing inventory levels, and maintaining production schedules.
In addition, roll forming machines, uncoilers, coil cars, flatteners, roll form dies, roll formers, and presses are essential equipment in the pharmaceutical industry. These machines enable the production of high-quality pharmaceutical components, ensuring the production of effective and safe medicines. Customer service plays a crucial role in the market. Providers of pharmaceutical equipment must ensure that their equipment meets the highest standards of quality and reliability. Bob Repovs, a leading equipment sales representative, prioritizes the importance of providing excellent customer service to meet the unique needs of each client. Regulations and compliance requirements are a significant factor in the market.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product Type

  Solid
  Liquid


Type

  Packaging equipment
  Granulating equipment
  Spray drying equipment
  Filing machines
  Others


End-User

  Pharmaceutical manufacturing companies
  Contract manufacturing organizations


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Product Type Insights

The solid segment is estimated to witness significant growth during the forecast period.The market encompasses the production of equipment used in the manufacturing of Oral Solid Dosage (OSD) forms of pharmaceuticals. OSD forms, including tablets, capsules, and powders, offer advantages such as ease of administration, stability, accurate dosing, and controlled release. Notable companies in this sector include Syngenton, GEA Group, Romaco, and Korber. OSD forms are preferred due to their user-friendly nature, as they are simple to handle and require minimal preparation time. This attribute enables patients to self-administer medication at home, enhancing convenience and autonomy. The integration of technologies such as automation, robotics, artificial intelligence, and machine learning further streamlines the manufacturing process, ensuring efficiency and precision.

Get a glance at the market report of share of various segments Request Free Sample

The solid segment was valued at USD 7.50 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

Asia is estimated to contribute 37% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

Another region contributing to the market growth is North America. The North American market is primarily driven by the presence of a significant number of large-scale pharmaceutical and biotechnology companies based in the United States. One notable example is Pfizer Inc., a leading global pharmaceutical company headquartered in New York, which utilizes a wide range of phar

This statistic shows the spendings on R&D in the pharmaceutical industry in the United States, Europe and Japan from 2000 to 2013. In 2000, expenditiure on research and development in these countries came to a total of some 45 billion U.S. dollars.

Snapshot img

Bio-pharma Market Size 2024-2028

The bio-pharma market size is forecast to increase by USD 204.09 billion at a CAGR of 7.98% between 2023 and 2028.

The market is experiencing significant growth driven by the increasing prevalence of health disorders and the rise in the production of vaccines. The global population is aging, leading to an increase in chronic diseases such as cancer, type 2 diabetes, and cardiovascular diseases. This trend is particularly prominent in developed markets like the US, where an aging population and rising healthcare costs are fueling demand for innovative and effective bio-pharmaceutical solutions. Another key driver for the market is the production of vaccines, which has gained significant momentum in recent years due to the ongoing COVID-19 pandemic.
The rapid development and distribution of vaccines have highlighted the critical role of the bio-pharma industry in addressing global health crises. However, the high cost of bio-pharmaceuticals remains a significant challenge for market growth. This issue is compounded by regulatory requirements and lengthy approval processes, which can delay the entry of new products and limit competition. To capitalize on market opportunities and navigate challenges effectively, companies in the market must focus on innovation, cost reduction, and regulatory compliance. Strategic partnerships, collaborations, and acquisitions can help companies leverage each other's strengths and resources to bring new products to market more quickly and cost-effectively.

What will be the Size of the Bio-pharma Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of therapeutic modalities, including monoclonal antibodies, recombinant growth factors, purified proteins, recombinant enzymes, vaccines, recombinant hormones, cell therapies, gene therapies, synthetic immunomodulators, and various other living organisms derived from bacteria, yeast, and mammalian cells. Biotechnological processes are employed to produce these complex molecules, which target specific biological pathways, receptors, and molecular structures. Biopharmaceuticals address a broad spectrum of diseases, such as cancer, diabetes, psoriasis, rheumatoid arthritis, genetic mutations, and various other conditions.
Personalized medicine and the identification of biomarkers have significantly influenced the market's growth trajectory. The market's size and direction reflect the ongoing advancements in technology and the increasing demand for innovative therapeutic solutions.

How is the Bio-pharma Industry segmented?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Monoclonal antibodies
  Recombinant growth factors
  Vaccines
  Recombinant hormones
  Others


Application

  Oncology
  Autoimmune disorder
  Metabolic disorder
  Hormonal disorder
  Others


Geography

  North America

    US


  Europe

    France
    Germany


  Asia
  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies represent a significant segment of the market due to their high price point and life-saving capabilities, despite lower sales volumes compared to other pharmaceuticals. Revenues from monoclonal antibodies are substantial, making them a valuable contribution to the industry. The monoclonal antibodies segment is projected to grow during the forecast period, with companies investing heavily in research and development (R&D) of biologic drugs. Monoclonal antibodies hold the largest share in this area, as companies focus on expanding their bio-pharmaceutical domains.

Key therapeutic areas for monoclonal antibodies include oncology, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, neurological diseases, and chronic conditions such as dementia and Alzheimer's disease. Technologies such as high throughput screening, combinatorial chemistry, computational modeling, genomics, next-generation sequencing, gene editing techniques, and purified proteins are essential in the development and production of monoclonal antibodies and other biopharmaceuticals.

Get a glance at the market report of share of various segments Request Free Sample

The Monoclonal antibodies segment was valued at USD 151.68 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights

Success.ai’s Pharma Data for the Global Pharmaceutical Industry provides a robust dataset tailored for businesses looking to connect with pharmaceutical companies, decision-makers, and key stakeholders worldwide. Covering pharmaceutical manufacturers, research organizations, biotech firms, and distributors, this dataset offers verified SIC codes, firmographic details, and contact information for executives and operational leads.

With access to over 170 million verified professional profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and business development strategies are driven by reliable, continuously updated, and AI-validated data. Supported by our Best Price Guarantee, this solution is essential for navigating the competitive global pharmaceutical landscape.

Why Choose Success.ai’s Pharma Data?

1. Verified Contact Data for Precision Outreach

   • Access verified work emails, phone numbers, and LinkedIn profiles of pharmaceutical executives, R&D leads, compliance officers, and procurement managers.
   • AI-driven validation ensures 99% accuracy, optimizing your campaigns and improving communication efficiency.

2. Comprehensive Coverage of the Global Pharmaceutical Sector

   • Includes profiles of pharmaceutical companies, biotech firms, contract manufacturing organizations (CMOs), and distributors across North America, Europe, Asia, and other major markets.
   • Gain insights into regional pharmaceutical trends, product pipelines, and market dynamics unique to global markets.

3. Continuously Updated Datasets

   • Real-time updates reflect leadership changes, mergers, product launches, and regulatory compliance shifts.
   • Stay aligned with the fast-paced pharmaceutical industry to capitalize on emerging opportunities and maintain relevance.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible use of data and compliance with legal standards.

Data Highlights:

• 170M+ Verified Professional Profiles: Engage with decision-makers, R&D specialists, and operational leaders in the pharmaceutical industry worldwide.
• 30M Company Profiles: Access detailed firmographic data, including company sizes, revenue ranges, and geographic footprints.
• Verified SIC Codes: Understand industry classifications and product specializations to refine your targeting strategies.
• Leadership Contact Details: Connect with CEOs, COOs, medical directors, and regulatory managers influencing pharmaceutical operations.

Key Features of the Dataset:

1. Decision-Maker Profiles in Pharmaceuticals

   • Identify and engage with professionals overseeing R&D, clinical trials, supply chains, and regulatory compliance.
   • Target leaders responsible for drug development, vendor selection, and market entry strategies.

2. Advanced Filters for Precision Targeting

   • Filter companies by industry segment (biotech, generic pharmaceuticals, vaccines), geographic location, or revenue size.
   • Tailor campaigns to align with specific needs such as drug pipeline acceleration, production scaling, or market expansion.

3. SIC Codes and Firmographic Insights

   • Access verified SIC codes and detailed company profiles to understand market focus, operational scale, and specialization areas.
   • Use firmographic data to prioritize high-value targets and align product offerings with market demands.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data allow for personalized messaging, highlight unique value propositions, and improve engagement outcomes with pharmaceutical stakeholders.

Strategic Use Cases:

1. Sales and Lead Generation

   • Offer technology solutions, research tools, or contract services to pharmaceutical manufacturers, R&D facilities, and distribution networks.
   • Build relationships with procurement teams and compliance officers responsible for vendor approvals and operational excellence.

2. Market Research and Product Development

   • Analyze global pharmaceutical trends, drug approval patterns, and regulatory frameworks to guide product innovation and market entry strategies.
   • Identify high-growth regions and emerging therapeutic areas to focus your resources effectively.

3. Partnership and Supply Chain Development

   • Connect with pharmaceutical companies seeking contract manufacturing, raw material sourcing, or distribution partnerships.
   • Foster alliances that streamline production, ensure quality, and accelerate time-to-market.

4. Regulatory Compliance and Risk Mitigation

   • Engage with regulatory officers and compliance managers overseeing adherence to local and international pharmaceutical standards.
   • Present solutions for documentation, reporting, and risk management to ensure compliance and operational efficiency.

Why Choose Success.ai?

1. Best Price Guarantee
   ...

Snapshot img

Pharmaceutical Contract Packaging Market Size 2024-2028

The pharmaceutical contract packaging market size is forecast to increase by USD 9.32 billion at a CAGR of 16.54% between 2023 and 2028.

The global pharmaceutical contract packaging market is experiencing steady growth, driven by rising R&D investments in the pharmaceutical industry and advancements in specialized packaging technologies. Key factors include the increasing trend of outsourcing packaging to reduce costs and improve efficiency, alongside growing demand for innovative solutions like child-resistant and anti-counterfeit packaging, spurred by regulatory requirements and market expansion.
This report provides a detailed resource for businesses, offering insights into market size, growth forecasts through 2028, and key segments like plastic bottles, which lead due to their cost-effectiveness and safety features. It explores trends such as the shift toward green packaging and addresses challenges like the high cost of advanced anti-counterfeit technologies, which can strain budgets but are critical for product integrity. The analysis is tailored for strategic planning, supply chain optimization, and market positioning.
For companies aiming to stay competitive in the global pharmaceutical contract packaging market, this report delivers practical data and perspectives on leveraging outsourcing trends and overcoming technological cost barriers, ensuring they can adapt to a dynamic and regulated landscape.

What will be the Size of the Pharmaceutical Contract Packaging Market During the Forecast Period?

Request Free Sample

The market's sizeable investment in production capacity expansion reflects the growing demand for packaging services for bioproducts, oncology drugs, high-potency drugs, antibody conjugates, steroids, and generic pharmaceuticals. Additionally, the growing demand for specialty pharmaceuticals, oncology drugs, vaccines, and biotech products is fueling the market, particularly in the areas of autoinjectors and pouches. The pharmaceutical packaging industry is also being influenced by the FMCG sector and health insurance trends, as insurers look for cost-effective solutions to manage drug delivery and distribution. Overall, the market for pharmaceutical contract packaging is expected to continue its growth trajectory, driven by these trends and challenges. Contract businesses offering ancillary services, such as bottle filling (plastic and glass), are also experiencing significant growth.

How is this Pharmaceutical Contract Packaging Industry segmented?

The pharmaceutical contract packaging industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Packaging

  Plastic bottles
  Blister packs
  Pouches
  Parenteral containers
  Pre-filled syringes


Type

  Primary
  Secondary
  Tertiary


Material

  Plastics & Polymers
  Paper & Paperboard
  Glass
  Aluminum Foil
  Others


Geography

  North America

    US
    Canada


  APAC

    China
    India
    Japan


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa



  South America

By Packaging Insights

The plastic bottles segment is estimated to witness significant growth during the forecast period. Pharmaceutical contract packaging involves the provision of services for manufacturing, filling, and packaging pharmaceutical products by third-party companies. Plastic bottles, made from low-density polyethylene (LDPE), high-density polyethylene, or polypropylene materials, are commonly used as primary packaging for solid, liquid, and semi-liquid pharmaceuticals. Some contract packaging companies manufacture these bottles in-house, while others procure them from suppliers and offer only packaging services. The demand for plastic bottles is on the rise In the pharmaceutical industry due to their benefits, such as eliminating the need for tertiary packaging and ensuring product safety throughout the supply chain.

Pharmaceutical packaging materials, including silicone-based and sustainable options, are essential for the industry's growth, particularly for bioproducts, generic pharmaceuticals, and injectables. Cloud packaging companies offer flexible, profitable solutions for pharmaceutical corporations, enabling capacity expansions and innovation in drug delivery systems. The global pharmaceutical industry's growth, driven by economic growth, an aging population, and healthcare systems, increases the demand for contract packaging services. Contract packaging companies provide ancillary services, including autoinjectors, prefilled syringes, and specialized manufacturing, to meet the industry's evolving needs.

The industry's supply chain requires specialized equipment, log keeping, and da

The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transitions which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference for generics compared to their branded versions. As a result of these transformations; the need for a user friendly, robust and comprehensive pharmaceutical market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the pharmaceutical market in some form or the other.

IMARC Group, one of the world’s leading research and advisory firms, introduces a new and revolutionary way to understand and evaluate the global pharmaceutical market with its Microsoft Excel based report entitled “Global Pharmaceutical Market Report & Forecast: 2012-2017”. This report provides an analytical and statistical insight into the global pharmaceutical market. The study, which has been undertaken using desk based as well as primary market research has analyzed the following aspects of the global pharmaceutical market.

What We Have Achieved in This Report?

Regions Covered: Global, North America, Europe, Asia Pacific, Latin America & Caribbean and Middle East & Africa

Countries Covered in Each Region

North America: United States and Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Netherlands, Poland, Greece, Belgium, Switzerland, Austria, Sweden, Portugal, Hungary, Romania, Denmark, Czech Republic, Finland, Ireland, Norway, Slovakia, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Luxembourg and Estonia

Asia Pacific: Japan, China, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Pakistan, Vietnam, Bangladesh, Hong Kong, New Zealand, Malaysia and Singapore

Latin America & Caribbean:Brazil, Mexico, Venezuela, Argentina, Puerto Rico, Colombia, Chile, Ecuador, Peru, Dominican Republic and Uruguay

Middle East & Africa: South Africa, Egypt, Saudi Arab, Algeria, Morocco, United Arab Emirates Lebanon, Tunisia, Jordan and Kuwait

Focus of the Analysis:

• Historical sales performance (2007-2011) for each country
• Historical sales performance (2007-2011) for each region
• Sales forecast (2012-2017) for each country
• Sales forecast (2012-2017) for each region
• Sales performance of key manufacturers for each country (2007-2011)
• Sales performance of key therapeutic areas for each country (2007-2011)
• Country wise sales breakup for each region (2007-2011)
• Country wise sales breakup forecast for each region (2012-2017)

Key Questions Answered;

• What was the historical performance of the global pharmaceutical market?
• Which are the key regions and countries in the global pharmaceutical market?
• Which are the largest pharmaceutical markets in the world?
• Which are the fastest growing pharmaceutical markets in the world?
• Which markets are expected to witness the slowest growth in the coming years?
• Which countries represent the key markets for each region?
• What has been the performance of various therapeutic classes in each country?
• Who are the top pharmaceutical manufacturers in each country?
• What are the market shares of the top pharmaceutical manufacturers in each country?

Why You should Buy This Report?

• To gain a comprehensive understanding on the historical, current and future pharmaceutical market trends across 70 countries in 6 regions.
• To identify potential regions, countries, therapeutic areas, partners and competitors for market entry and expansion plans.
• As a tool for developing investment strategies by identifying the biggest winners and losers across various regions and countries.
• To ensure a successful M&A and partnership strategy by identifying therapeutic areas and companies with the most promising outlook.

The global pharmaceutical contract manufacturing market, valued at $136.09 billion in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2033. This expansion is fueled by several key drivers. The increasing complexity of drug development necessitates outsourcing for specialized manufacturing processes and technologies, especially for biopharmaceuticals and advanced therapies. Furthermore, the rising demand for generic drugs and the cost-optimization strategies adopted by pharmaceutical companies are significant contributors to market growth. Growing regulatory scrutiny and the need to maintain compliance further encourage companies to leverage the expertise of contract manufacturers, ensuring quality and efficiency. The market's segmentation reflects this diversity, with large pharmaceutical companies, smaller and medium-sized enterprises, and generic drug manufacturers all relying heavily on contract manufacturing services. Geographic expansion, particularly in emerging markets with growing healthcare infrastructure and pharmaceutical industries, also contributes to the market's upward trajectory. Competition amongst contract manufacturers is intense, necessitating continuous innovation and the adoption of advanced technologies to maintain a competitive edge. This dynamic market landscape presents both opportunities and challenges, requiring strategic planning and adaptability to succeed. The North American market currently holds a significant share due to established infrastructure and a strong regulatory framework. However, the Asia-Pacific region, particularly India and China, is expected to witness rapid growth driven by increasing domestic demand and the presence of a large pool of skilled labor. European markets, though mature, remain vital contributors. This geographical spread underscores the global nature of the pharmaceutical industry and the correspondingly diverse opportunities and challenges in the contract manufacturing sector. The successful players in this market will be those that effectively navigate regulatory compliance, leverage technological advancements, and adapt to the ever-evolving needs of their diverse client base across multiple geographic regions. Future growth will likely be influenced by technological innovation in areas like advanced drug delivery systems, personalized medicine, and cell and gene therapies, which will further increase demand for specialized contract manufacturing services.

As of 2024, 125 pharmaceutical and biotechnological companies were among the leading 800 companies in the European Union. France had the highest number of leading pharmaceutical and biotechnological companies in that year, with 29 companies listed. Leading markets Despite not having the highest amount of leading pharma companies in Europe, Germany was the leading pharmaceutical market in Europe, with total revenues of some 69 billion euros in 2023. France and Italy followed with revenues of around 46 billion and 41 billion euros, respectively. The United Kingdom and Spain are the next big European markets. Development in pharmaceuticals in Europe In 2023, nearly 2,800 pharmaceutical patents were granted by the European Patent Office. Interestingly, the country with the highest number of European pharmaceutical patents granted was the United States at 957, followed by 231 patents granted to Japanese companies.

Swiss companies Roche and Novartis held the second and third place among European pharma and biotech companies, accumulating a market capitalization of approximately 255 billion U.S. dollars, each. This statistic shows the leading pharmaceutical and biotechnology companies from Europe as of September 2024, based on market capitalization.

The Pharmaceutical Manufacturing Software Market is Segmented by Product (On-Cloud, and On-Premises), By Enterprise (Large Enterprise, and Small and Medium-Sized Enterprises (SMEs)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD million) for the above segments.

Snapshot img

Pharmaceutical Traceability Market 2024-2028

The global pharmaceutical traceability market size is estimated to grow by USD 17.92 billion at a CAGR of 23.44% between 2023 and 2028.

Globally, pharmaceutical companies are witnessing significant growth. The increasing prevalence and incidence of various chronic diseases, such as cancer, heart disease, diabetes, arthritis, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, and dementia, have increased the need to develop new drugs for their treatment. To treat these chronic diseases, pharmaceutical companies are increasingly focusing on developing generic and over-the-counter (OTC) drugs for various therapeutic applications. Further, rapid growth in drug development has increased the need for pharmaceutical companies to ensure brand protection due to counterfeiting. This is increasing the demand for various advanced technologies, including printing technologies and digital scanning, to protect pharmaceutical products from counterfeiting. Hence, the rising focus of pharmaceutical companies on brand protection is fostering the growth of the market during the forecast period.

Technavio has segmented the market into Type, Application, and Geography

The type segment is classified into barcode, RFID, GPS, and biometrics and others
The application segment is classified into pharmaceutical factories, hospitals, pharmacies, and others
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Pharmaceutical Traceability Market During the Forecast Period?

To learn more about this report, Download Report Sample

Pharmaceutical Traceability Market Segmentation by Type, Application and Geography Analysis

Type Analysis

Barcode

The market share growth by the barcode segment will be significant during the forecast period. Barcodes are a series of vertical lines or bars with different widths that can be read by an optical scanner. The width and spacing of the bars represent binary data. The scanners are connected to computers. These scanners decode the barcodes to give the necessary information regarding the product.

Get a glance at the market contribution of various segments Download PDF Sample

The barcode was the largest segment and was valued at USD 1.71 billion in 2018. Barcodes have been widely accepted by end-users because of their relatively lower cost when compared with RFID tags, their lightweight nature for ease of use, and their high accuracy levels on different material surfaces. Also, the government has promoted the use of barcodes in the pharmaceutical industry by introducing new initiatives and laws. Barcodes facilitate efficient tracking and identification of pharmaceutical products, aiding in supply chain management and reducing the risk of counterfeit drugs. Additionally, regulatory mandates for serialization and traceability further propel the growth of barcode solutions, making them a practical and widely accepted technology in pharmaceutical traceability efforts worldwide. Such factors will fuel the growth of the barcode segment of the market during the forecast period.

Application

Pharmaceutical factories

The pharmaceutical factories segment in the global pharmaceutical traceability market is witnessing increased demand due to several compelling factors. Firstly, regulatory compliance is a major driver in the growth of the pharmaceutical factories segment, as pharmaceutical manufacturers must adhere to stringent regulations to ensure the safety and authenticity of their products. Secondly, the rising prevalence of counterfeit drugs is a significant concern in the pharmaceutical industry. Pharmaceutical factories are adopting traceability solutions to enhance operational efficiency and supply chain visibility. Accurate tracking and monitoring of the production processes, inventory, and distribution contribute to streamlined operations, reduced errors, and improved overall efficiency. Thus, stringent regulatory requirements, the need to combat counterfeit drugs, and a focus on enhancing operational efficiency will drive the growth of the global pharmaceutical traceability market through the pharmaceutical factories segment during the forecast period.

Hospitals

The hospital segment in the global pharmaceutical traceability market is witnessing increased demand due to various factors contributing to the overall safety, efficiency, and effectiveness of healthcare delivery. Patient safety is paramount in hospitals, and accurate traceability ensures that the right medications are administered to the right patients at the right time. Further, instances of increasing demand for pharmaceutical traceabili

According to Cognitive Market Research, the global Pharmaceutical CXO market size will be USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 15.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.7% from 2024 to 2031.
The CRO category is the fastest growing segment of the Pharmaceutical CXO industry

Market Dynamics of Pharmaceutical CXO Market

Key Drivers for Pharmaceutical CXO Market

Growing Demand for Biologics and Specialty Drugs to Boost Market Growth

The increasing development and production of biologics, including biosimilars, has significantly boosted the demand for specialized Contract Manufacturing Organization (CMO) services. Recent data reveals that therapeutic areas with biosimilars introduced in the past three years see an average market share of 75%. In contrast, therapeutic areas with biosimilars launched before 2019 have experienced a lower average market share of 39% over three years. In the U.S., the presence of biosimilars has led to substantial savings in drug expenditures, with an estimated $21 billion saved over the past six years due to biosimilar competition. For just the second quarter of 2022, the savings in drug spending reached approximately $3.2 billion. Both the EU and U.S. markets account for 90% of cumulative biosimilar usage, measured by sales. These trends underscore the growing demand for advanced manufacturing technologies and expertise required to produce complex biologic drugs. As a result, the global Pharmaceutical CxO market is expected to see increased growth. The rise in biosimilars drives the need for CMOs with specialized capabilities to handle the complexities of biologic production, thus creating significant opportunities for growth and expansion in the CxO sector.

Increasing Drug Development Costs and Complexity to Drive Market Growth

The cost of developing new drugs has significantly increased due to the growing complexity of drug development and rigorous regulatory demands. In 2019, the pharmaceutical industry invested $83 billion in research and development (R&D). When adjusted for inflation, this figure is approximately ten times higher than the annual R&D spending of the 1980s. During the twelve months from July 2021 to July 2022, 1,216 products saw price increases that surpassed the inflation rate of 8.5% for that period. On average, the price of these drugs rose by 31.6%. In some cases, drug prices surged by over $20,000, representing a dramatic increase of up to 500%. To manage these escalating costs, pharmaceutical companies are increasingly relying on Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs). These organizations provide specialized expertise and advanced technologies that streamline the drug development process, helping to reduce both costs and time-to-market.

Restraint Factor for the Pharmaceutical CXO Market

Regulatory and Compliance Challenges Will Limit Market Growth

The pharmaceutical industry is highly regulated, and compliance with global and regional regulations can be complex and costly. CROs and CMOs must navigate various regulatory requirements across different markets, which can lead to delays and increased operational costs. Regulatory standards are constantly evolving, and staying compliant with these changes requires continuous updates to processes and systems, adding to operational complexity and costs. Ensuring consistent quality across different CROs and CMOs can be challenging. Variability in quality standards and practices among service provi...